ClinicalTrials.gg
CompletedNCT02472886Updated Nov 16, 2018Results posted

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

A Phase 3 interventional study of LDV/SOF and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
153
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.

Enrollment
51st of 174
153 · median 78
Started
2015
with 19 others
Phase 3
56 of 174
none open now
Registered
147th of 174
by date
Lead sponsor
15 of 174
Gilead Sciences

Among the 174 studies testing ribavirin in Hepatitis C, this one is the 51st largest by enrollment, is one of 20 that started in 2015, is one of 56 in phase 3, and was the 147th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 174 studies testing ribavirin in Hepatitis C as a file.
02

Study summary

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in adults with chronic hepatitis C virus (HCV) infection.

03

Conditions studied

  • Hepatitis C Virus Infection

Keywords

  • HCV genotype 1
  • HCV
  • Sustained Virologic Response
  • Direct Acting Antiviral
  • Combination Therapy
  • GS-7977
  • GS-5885
  • Ribavirin
  • Sofosbuvir
  • ledipasvir
  • Hepatitis C
  • Hepatitis C, Chronic
  • Liver Diseases
  • Virus Diseases
  • Antiviral Agents
  • HCV/HIV co-infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants who failed treatment in Study GS-US-334-0119 who meet relevant inclusion/exclusion criteria are eligible for retreatment in this study
  • Chronic genotype 1 infection
  • HCV treatment-naive
  • HCV RNA > 10,000 IU/mL at screening
  • Absence of cirrhosis
  • Screening laboratory values within defined thresholds
  • Use of two effective methods if female of or sexually active male

Key Exclusion Criteria:

  • Pregnant or nursing female or male with pregnant female partner
  • Infection with virus (HBV)
  • Current or prior history of clinical hepatic decompensation
  • Chronic use of systemic agents
  • History of illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol
  • For -1/HCV co-infected individuals:

    • Opportunistic infection within 6 months prior to screening
    • Active, serious infection (other than HIV-1 or HCV) requiring parental antibiotics, antivirals or antifungals within 30 days prior to baseline
    • Treatment with an antiretroviral (ARV) regimen other than one of those listed in the study protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    LDV/SOF

    Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.

    Drug: LDV/SOF

  • Experimental
    LDV/SOF Coinfected with HIV-1

    Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.

    Drug: LDV/SOF

  • Experimental
    LDV/SOF+RBV Retreatment

    Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.

    Drug: LDV/SOF · Drug: RBV

Interventions

  • DrugLDV/SOF

    90/400 mg FDC tablet administered orally once daily

    Also known as: Harvoni®, GS-5885/GS-7977

  • DrugRBV

    Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Discontinued Study Drug Due to Any Adverse Event (AE)

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)

    SVR4 and SVR24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.

    Time frame: Posttreatment Weeks 4 and 24

  2. Percentage of Participants With HCV RNA < LLOQ on Treatment

    Time frame: Up to 12 weeks

  3. HCV RNA Change From Day 1

    Time frame: Up to 12 weeks

  4. Percentage of Participants With Virologic Failure

    Virologic failure was defined as * On-treatment virologic failure * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough), * confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse) * Relapse * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement

    Time frame: Up to Posttreatment Week 24

  5. Percentage of HIV/HCV- Coinfected Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment and at Posttreatment Week 4

    Time frame: Up to Posttreatment Week 4

  6. For HIV/HCV- Coinfected Participants, Change From Baseline in CD4 T-cell Count at the End of Treatment and Posttreatment Week 4

    Time frame: Up to Posttreatment Week 4

07

Results

Posted May 10, 2017

Participant flow

Participants were enrolled at study sites in Russia and Estonia. The first participant was screened on 17 June 2015. The last study visit occurred on 30 June 2016.

Participant flow — Overall Study
MilestoneLDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)
Started675927
Completed675726
Not completed021
Withdrew: Lack of efficacy021

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participantsLDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)100.0 (94.6 to 100.0)96.6 (88.3 to 99.6)96.3 (81.0 to 99.9)
PrimaryPercentage of Participants Who Discontinued Study Drug Due to Any Adverse Event (AE)
Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Study Drug Due to Any Adverse Event (AE)
percentage of participantsLDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)
Percentage of Participants Who Discontinued Study Drug Due to Any Adverse Event (AE)000
SecondaryPercentage of Participants With Sustained Virologic Response (SVR) at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)

SVR4 and SVR24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.

Time frame:
Posttreatment Weeks 4 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
percentage of participantsLDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)
SVR4100.0 (94.6 to 100.0)96.6 (88.3 to 99.6)96.3 (81.0 to 99.9)
SVR24100.0 (94.6 to 100.0)96.6 (88.3 to 99.6)96.3 (81.0 to 99.9)
SecondaryPercentage of Participants With HCV RNA < LLOQ on Treatment
Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ on Treatment
percentage of participantsLDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)
Week 120.9 (11.9 to 32.6)39.0 (26.5 to 52.6)3.7 (0.1 to 19.0)
Week 265.7 (53.1 to 76.8)69.5 (56.1 to 80.8)59.3 (38.8 to 77.6)
Week 4100.0 (94.6 to 100.0)96.6 (88.3 to 99.6)88.9 (70.8 to 97.6)
Week 8100.0 (94.6 to 100.0)98.3 (90.9 to 100.0)100.0 (87.2 to 100.0)
Week 12NA (NA to NA)NA (NA to NA)100.0 (87.2 to 100.0)
SecondaryHCV RNA Change From Day 1
Time frame:
Up to 12 weeks
Reported as:
Mean · log10 IU/mL
HCV RNA Change From Day 1
log10 IU/mLLDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)
Week 1-3.97 ± 0.675-4.34 ± 0.626-4.12 ± 0.582
Week 2-4.50 ± 0.687-4.76 ± 0.522-4.83 ± 0.630
Week 4-4.74 ± 0.723-4.89 ± 0.534-5.08 ± 0.642
Week 8-4.74 ± 0.723-4.91 ± 0.536-5.11 ± 0.671
Week 12NA ± NANA ± NA-5.11 ± 0.671
SecondaryPercentage of Participants With Virologic Failure

Virologic failure was defined as * On-treatment virologic failure * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough), * confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse) * Relapse * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Failure
percentage of participantsLDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)
Percentage of Participants With Virologic Failure03.43.7
SecondaryPercentage of HIV/HCV- Coinfected Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment and at Posttreatment Week 4
Time frame:
Up to Posttreatment Week 4
Reported as:
Number · percentage of participants
Percentage of HIV/HCV- Coinfected Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment and at Posttreatment Week 4
percentage of participantsLDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)
Week 4100.0
Week 8100.0
Posttreatment Week 497.2
SecondaryFor HIV/HCV- Coinfected Participants, Change From Baseline in CD4 T-cell Count at the End of Treatment and Posttreatment Week 4
Time frame:
Up to Posttreatment Week 4
Reported as:
Mean · cells/µL
For HIV/HCV- Coinfected Participants, Change From Baseline in CD4 T-cell Count at the End of Treatment and Posttreatment Week 4
cells/µLLDV/SOF 8 Weeks (TN, HCV/HIV-coinfected, ARV- Naive)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected, ARV Experienced)
Change at Week 447 ± 120.5159 ± 114.9
Change at Week 845 ± 122.7202 ± 178.1
Change at Posttreatment Week 474 ± 117.8172 ± 114.1

Adverse events

Collected over Up to 12 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDV/SOF 8 Weeks (TN, HCV-monoinfected)0/67 (0%)0/67 (0%)5/67 (7.5%)
LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)0/59 (0%)0/59 (0%)2/59 (3.4%)
LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)0/27 (0%)0/27 (0%)8/27 (29.6%)
Most frequent other events
Most frequent other events
EventLDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)
HeadacheNervous system disorders4/670/594/27
DyspepsiaGastrointestinal disorders0/670/593/27
Abdominal pain upperGastrointestinal disorders1/671/592/27
AstheniaGeneral disorders1/670/592/27
Blood bilirubin increasedInvestigations0/670/592/27
IrritabilityPsychiatric disorders0/671/592/27

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)LDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)Total
Mean42 ± 12.634 ± 5.547 ± 11.240 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)LDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)Total
Female3325967
Male34341886
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)Total
White665927152
Asian1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)Total
Not Hispanic or Latino675927153
Region of Enrollment
Region of Enrollment(Participants)LDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)Total
Russian Federation614727135
Estonia612018
IL28b Status
IL28b Status(Participants)LDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)Total
CC179733
CT414118100
TT99220
HCV RNA
HCV RNA(log10 IU/mL)LDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)Total
Mean5.9 ± 0.726.1 ± 0.546.3 ± 0.676.0 ± 0.66
HCV RNA Category
HCV RNA Category(Participants)LDV/SOF 8 Weeks (TN, HCV-monoinfected)LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected)LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected)Total
< 800,000 IU/mL2923860
≥ 800,000 IU/mL38361993

1 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • Tallinn, 10167, Estonia
  • Tartu, 51014, Estonia
  • Ekaterinburg, 620102, Russian Federation
  • Krasnoyarsk, 660049, Russian Federation
  • Moscow, 105275, Russian Federation
  • Moscow, 107014, Russian Federation
  • Moscow, 111123, Russian Federation
  • Moscow, 115446, Russian Federation
  • Moscow, 117593, Russian Federation
  • Moscow, 119435, Russian Federation
  • Moscow, 119991, Russian Federation
  • Moscow, 125367, Russian Federation
  • Moscow, 127015, Russian Federation
  • Moscow, 129090, Russian Federation
  • Moscow, 129110, Russian Federation
  • Samara, 443063, Russian Federation
  • St. Petersburg, 190103, Russian Federation
  • St.petersburg, 194044, Russian Federation
  • Stavropol, 355017, Russian Federation
  • Tyumen, 625026, Russian Federation
09

References and documents

Publications

  • Zhdanov K., Morozov V., Orlova-Morozova E.A., Salupere R., Kozhevnikova G., et al. Preliminary Results of an Evaluation of Ledipasvir/Sofosbuvir in Treatment-Naive Patients with Chronic HCV or HCV/HIV Co-Infection and Retreatment of Sofosbuvir-treated Patients. 8th International Conference of the White Nights of Hepatology. Saint Petersburg, Russia. June 2-3, 2016. Oral presentation.
  • Isakov V, Gankina N, Morozov V, Kersey K, Lu S, Osinusi A, Svarovskaia E, Brainard DM, Salupere R, Orlova-Morozova E, Zhdanov K. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection +/- HIV-1 Co-Infection. Clin Drug Investig. 2018 Mar;38(3):239-247. doi: 10.1007/s40261-017-0606-0. Erratum In: Clin Drug Investig. 2021 Mar;41(3):291. doi: 10.1007/s40261-021-01014-9. PubMed 29177645 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Mar 2016, 9 months.

Results were first posted in May 2017, 1 year 1 month after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2015
First posted
Jun 16, 2015
StartActual
Jun 17, 2015
Primary completionActual
Mar 30, 2016
CompletionActual
Jun 30, 2016
Results first posted
May 10, 2017
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02472886
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 16, 2015
Start date
Jun 17, 2015
Primary completion
Mar 30, 2016
Completion
Jun 30, 2016
Results posted
May 10, 2017
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribavirin

Start the discussion